Skip to main content

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's "robust" neuroscience pipeline adds medications that may transform standards of care in psychiatric and neurological illnesses.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.